When I read that a peptide is 'in phase 2', what does that actually mean?
Updated: 2026-09-09 · Safety and evidence
Short answer
Each phase answers a different question. Phase 1: is it tolerable and what does the body do with it? Phase 2: does it seem to do something, and at what safety margin? Phase 3: does it really work against a comparator, in many people? Being in phase 2 means the important question has not been answered yet.
In plain English
- Phase 1: few participants, focused on safety and how the compound behaves in the body.
- Phase 2: mid-sized groups, first signals of effect plus more safety data.
- Phase 3: large numbers, formal comparison, the basis for a possible approval.
- Phase 4: post-approval monitoring in the real population.
What we know
- The phased sequence is the standard of clinical research and is described this way by NIH and FDA.
- A high share of compounds entering phase 1 never reach approval.
What we don't know yet
- Being in trials tells you nothing reliable about the eventual result.
- Many popular peptides have no registered trial for the use they are marketed for.
Sources
External links to official sources or peer-reviewed studies.